Review section,Disease,Target gene,Action,Effector construct,Nucleic acids binding protein,Type of delivery ,Organism,References,DOI link,Graph. abstract link
3.1. Hereditary Disorders: Haploinsufficiency,Dravet syndrome,Scn1a,activation,VP64,dSpCas9,dual AAV9-based system (Cas+sg),mouse,"Colasante G, Lignani G, et al. dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. (2020)",https://doi.org/10.1016/j.ymthe.2019.08.018,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d9/6952031/4180247add53/gr1.jpg
3.1. Hereditary Disorders: Haploinsufficiency,Dravet syndrome,Scn1a,activation,VPR,dSpCas9,AAV (sg),transgenic mice ,"Yamagata T, Raveau M, et aL. CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice. (2020)",https://doi.org/10.1016/j.nbd.2020.104954,https://ars.els-cdn.com/content/image/1-s2.0-S0969996120302291-gr1.jpg
3.1. Hereditary Disorders: Haploinsufficiency,Transcallosal discordance,Sema6a,activation,SunTag-VP64,dCas9,plasmid electroporation,mouse,"Peter, C.J., Saito, A., Hasegawa, Y. et al. In vivo epigenetic editing of Sema6a promoter reverses transcallosal dysconnectivity caused by C11orf46/Arl14ep risk gene. (2019)",https://doi.org/10.1038/s41467-019-12013-y,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-019-12013-y/MediaObjects/41467_2019_12013_Fig1_HTML.png?
3.1. Hereditary Disorders: Haploinsufficiency,hereditary obesity,"Sim1, Mc4r +/−",activation,VP65,dSaCas9,dual rAAV-based system (Cas+sg),"Sim1+/− mice, Mc4r +/−","Navneet Matharu et al. ,CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. (2019)",https://doi.org/10.1126/science.aau0629,https://www.science.org/cms/10.1126/science.aau0629/asset/d2634b15-b408-4643-b39a-0d051ea89601/assets/graphic/363_aau0629_fa.jpeg
3.2. Hereditary Disorders: Imprinting,Angelman syndrome,Ube3a-ATS,repression,KRAB,ZFN,dual AAV vein injection,Ube3a deletion C57BL/6J males mice,"O'Geen H, Beitnere U, et al. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model. (2023)",https://doi.org/10.1016/j.ymthe.2023.01.013,https://www.cell.com/cms/10.1016/j.ymthe.2023.01.013/asset/c1cd7206-e72b-46d9-9627-18d010b2535a/main.assets/fx1_lrg.jpg
3.2. Hereditary Disorders: Imprinting,Angelman syndrome,Ube3a-ATS,repression,SunTag-DNMT3A-DNMT3L,dCas9,mRNA-sgRNA LNP ,"Ube3ap+/m-, dCas9-SDD or “AS-dCas-SDD” mice","Liu, Y., Lou, S., Li, J. et al. Epigenetic editing alleviates Angelman syndrome phenotype in mice by unsilencing paternal Ube3a. (2024)",https://doi.org/10.1038/s41421-024-00727-3,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41421-024-00727-3/MediaObjects/41421_2024_727_Fig1_HTML.png
3.2. Hereditary Disorders: Imprinting,Angelman syndrome,Ube3a-ATS,repression,hfCas13x.1,hfCas13x.1,AAV-injection,Ube3a KO C57BL/6  male mice ,"Li J, Shen Z, Liu Y, et al. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice. (2023)",https://doi.org/10.1016/j.ymthe.2023.02.015,https://www.cell.com/cms/10.1016/j.ymthe.2023.02.015/asset/8ab298eb-6acf-4c3a-a805-5081286639a7/main.assets/fx1_lrg.jpg
3.2. Hereditary Disorders: Imprinting,Prader-Willi syndrome,SNRPN ,activation,VP64-dCas9-VP64,dCas9,nucleofection,iPSC,"View ORCID ProfileJacob Goell, Jing Li, et al. Tailoring a CRISPR/Cas-based Epigenome Editor for Programmable Chromatin Acylation and Decreased Cytotoxicity. (2024)",https://doi.org/10.1101/2024.09.22.611000,https://www.biorxiv.org/content/biorxiv/early/2024/09/22/2024.09.22.611000/F1.large.jpg?width=800&height=600&carousel=1
3.2. Hereditary Disorders: Imprinting,Silver-Russell syndrome,H19 -DMR,repression,SunTag-Tet1,dCas9,"tetraploid complementation, transient expression in fertilized eggs, stable expression in fertilized eggs",mice,"Horii, T., Morita, S., Hino, S. et al. Successful generation of epigenetic disease model mice by targeted demethylation of the epigenome. (2020)",https://doi.org/10.1186/s13059-020-01991-8,https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13059-020-01991-8/MediaObjects/13059_2020_1991_Fig1_HTML.png
3.3. Hereditary Disorders: X-linked,Duchenne muscular dystrophy (DMD,folistatine,activation,SAM (with modifications),dCas9,dual AAV9,mice,"Liao HK, et al. In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. (2017)",https://doi.org/10.1016/j.cell.2017.10.025,https://www.cell.com/cms/10.1016/j.cell.2017.10.025/asset/4c90254e-38e4-422d-9f8d-31452ee22bba/main.assets/fx1_lrg.jpg
3.3. Hereditary Disorders: X-linked,Duchenne muscular dystrophy (DMD,UTRN,activation,VPR,dCasMINI,local injection or tail vein intravenous injection,DMD mice,"Wu, R., Li, P., Xiao, P. et al. Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy. (2025)",https://doi.org/10.1038/s41467-025-57831-5,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-025-57831-5/MediaObjects/41467_2025_57831_Fig1_HTML.png
3.3. Hereditary Disorders: X-linked,Martin-Bell syndrome,FMR1,activation,Tet1,dCas9,transduction of iPSC - mice transplantation,mice,"Liu XS, Wu H, Krzisch M, et al. Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. (2018)",https://doi.org/10.1016/j.cell.2018.01.012,https://www.cell.com/cms/10.1016/j.cell.2018.01.012/asset/4dd44dc5-acc5-4192-9014-54c0b261c42a/main.assets/fx1_lrg.jpg
3.3. Hereditary Disorders: X-linked,Rett syndrome,MeCP2,repression,Tet1,dCas9,lentiviral  transduction,hESC-derived neurones,Junming Qian et al. Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. (2023),https://doi.org/10.1126/scitranslmed.add4666,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acb5/11975455/a61d108717fc/nihms-2062637-f0001.jpg
3.3. Hereditary Disorders: X-linked,Rett syndrome,MeCP2,repression,CTCF,dCpf1,lentiviral  transduction,hESC-derived neurones,Junming Qian et al. Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. (2023),https://doi.org/10.1126/scitranslmed.add4666,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acb5/11975455/a61d108717fc/nihms-2062637-f0001.jpg
3.3. Hereditary Disorders: X-linked,neurodevelopmental disorder CDKL5 deficiency,CDKL5 ,activation,Tet1,dCas9,lentiviral  transduction,U87MG,"Julian A N M Halmai, et al. Artificial escape from XCI by DNA methylation editing of the CDKL5 gene. (2020)",https://doi.org/10.1093/nar/gkz1214,https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/nar/48/5/10.1093_nar_gkz1214/1/m_gkz1214fig1.jpeg?Expires=1747980571&Signature=MBzyYQfWjX6Npm8bhTPvRXiPYkyNG~XVV-sQPDJcmlsAxyB5YOaw9-pXUSWKCx3eaSB78LYB60B0bDRMR6kmS3qeoiaL2OvaA89Kx~eQp4EZ-g~F8d9e3cecptK~GvCP9tCTe-ELimVw1YCEUAQlNw4xOkPBAqpBp~NdUMbUO-r2Jpw2i9A50edh3IR5qrh3wHvETs4N4EOEf6lN7ccfYfHvClyIst4l5ugZ3CSjCxyQAvXNfAWi5kMmE1q4coEIScC7VpcLQ4L5Wd7dUDlbRox6N6JxS~ShK6hvml40aSxjJs7gWjc8SG1fsv~u~8DybKsCnpKjbKN5fMEWpxCxLw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
3.4. Hereditary Disorders: Recessive Autosomal,Friedreich's ataxia,FXN,activation,VP64,TALE,Transfection,HEK293FT,"Tremblay JP, et al. Transcription activator-like effector proteins induce the expression of the frataxin gene. (2012)",https://doi.org/10.1089/hum.2012.034,
3.4. Hereditary Disorders: Recessive Autosomal,Friedreich's ataxia,FXN,activation,VP64,TALE,Nucleofection,Fibroblasts (GM04078) ,"Chapdelaine P, et al. A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins. (2013)",https://doi.org/10.1038/mtna.2013.41,https://www.cell.com/cms/10.1038/mtna.2013.41/asset/94bfdb50-264a-4057-b0e2-6e4b33bab726/main.assets/gr1_lrg.jpg
3.4. Hereditary Disorders: Recessive Autosomal,Friedreich's ataxia,FXN,activation,VP64,TALE,AAV9 intraperitoneal injection,YG8R mice,"Chapdelaine, P., Gérard, C., Sanchez, N. et al. Development of an AAV9 coding for a 3XFLAG-TALE-VP64 able to increase in vivo the human frataxin in YG8R mice. (2016)",https://doi.org/10.1038/gt.2016.36,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fgt.2016.36/MediaObjects/41434_2016_Article_BFgt201636_Fig1_HTML.jpg?
3.4. Hereditary Disorders: Recessive Autosomal,Congenital muscular dystrophy type 1A (MDC1A),Lama2,activation,2×VP64,SadCas9,AAV9-injection,dy2j/dy2j  mice ,"Kemaladewi, D.U., Bassi, P.S., Erwood, S. et al. A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene. (2019)",https://doi.org/10.1038/s41586-019-1430-x,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-019-1430-x/MediaObjects/41586_2019_1430_Fig1_HTML.png?
3.4. Hereditary Disorders: Recessive Autosomal,β-thalassemia and sickle cell disease (SCD),HbF,activation,VP64,ZF,Transfection,K562,"Gräslund T, Li X, Magnenat L, Popkov M, Barbas CF 3rd. Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. (2005)",https://doi.org/10.1074/jbc.M406809200,https://www.jbc.org/cms/10.1074/jbc.M406809200/asset/65d59405-8f3a-4572-95f3-9e04cb267b43/main.assets/gr1_lrg.jpg
3.4. Hereditary Disorders: Recessive Autosomal,β-thalassemia and sickle cell disease (SCD),HbF,activation,VP64,ZF,Lentiviral transduction,CD34+ cells,"Andrew W., Ulrich T., et al. A zinc-finger transcriptional activator designed to interact with the γ-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. (2010)",https://doi.org/10.1182/blood-2009-08-240556,https://ash.silverchair-cdn.com/ash/content_public/journal/blood/115/15/10.1182_blood-2009-08-240556/4/zh89991051670001.jpeg?Expires=1748847908&Signature=Neu3Xm~FW4kI6hlvyXXjr~o6BqScimd0PHVuB1-MpfRwIloy~2oBURl-M22oMuSSsI8wOX4FFPQqPup8OdhicjokIvz5HiE5uIzDxcvFAuq4dgD1-3aA~s7qq0R~n6mZVDxhjqGUJWSLW~cu3VJgy8wpAVu4Ey-iKPzMi7z1B83-XySdptLI4~xL8aSbh9T8hYw~QWqpD6zweHn~82GtZ~cSXKNGpUHJSi6zuWLYy1kWBmFrPE56yd50umR3fi-7k9RtACNm51Ke6Zoq9obKrmPN8s5Z2CTRBdMS7z37An-mkqyNJULCF78RuTDqZSN-1ndedd63YDWMPz6IZDDCMQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
3.4. Hereditary Disorders: Recessive Autosomal,β-thalassemia and sickle cell disease (SCD),BCL11A,repression (gene editing),Cas9,Cas9,RNP electroporation,human (ex vivo),"Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. (2020)","https://doi.org/10.1056/NEJMoa2031054
",https://www.nejm.org/cms/10.1056/NEJMoa2031054/asset/522a91a8-647a-4f2b-9206-ecf2f202365c/assets/images/large/nejmoa2031054_f1.jpg
3.5. Neurodegenerative Diseases,Huntington's disease,HTT,repression,KRAB,ZFN-KRAB,AAV injection,Mice ([B6CBA-Tg(HDexon1)62Gpb/3J),"M. Garriga-Canut, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. (2012)",https://doi.org/10.1073/pnas.1206506109,https://www.pnas.org/cms/10.1073/pnas.1206506109/asset/4a1b8a83-bdec-4000-ba68-d3cc2ca6e7bd/assets/graphic/pnas.1206506s109fig01.jpeg
3.5. Neurodegenerative Diseases,Huntington's disease,HTT,repression,KRAB,ZFN,nucleofection,Q111/Q7 cell line,"Zeitler, B., Froelich, S., Marlen, K. et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease. (2019)",https://doi.org/10.1038/s41591-019-0478-3,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-019-0478-3/MediaObjects/41591_2019_478_Fig1_HTML.png?
3.5. Neurodegenerative Diseases,Prion diseases,Prnp,repression,CHARM,ZFP/TALE/dCas9,intravenously AAV injection (ZFN-CHARM),"C57BL/6N mice (ZFN-CHARM)
HEK293 (CRISPR-CHARM), N2a (CRISPR-CHARM, TALE-CHARM)
","dwin N. Neumann et al. ,Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor. (2024)",https://doi.org/10.1126/science.ado7082,https://www.science.org/cms/10.1126/science.ado7082/asset/eaad9159-3414-4c11-bdfe-996cf3a254c8/assets/images/large/science.ado7082-fa.jpg
3.5. Neurodegenerative Diseases,Alzheimer's disease,MAPT,repression,KRAB,ZFP,AAV hippocampal injection,C57BL/6 mice,"Susanne Wegmann et al. ,Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. (2021)",https://doi.org/10.1126/sciadv.abe1611,https://www.science.org/cms/10.1126/sciadv.abe1611/asset/033c96ed-cdc4-4e96-9be0-6f60d813813c/assets/graphic/abe1611-f1.jpeg
3.5. Neurodegenerative Diseases,Alzheimer's disease,"ADAM9, ADAM17 and TFEB",activation,VPR,dCas9,,,"Duarte, Fábio. Multiplexed CRISPR activation of neuroprotective genes for Alzheimer's Disease (2018)",https://estudogeral.uc.pt/handle/10316/86445,
3.5. Neurodegenerative Diseases,Parkinson's disease,"Ascl1, Lmx1a, Nr4a2",activation,SAM,intein-split-dCas9,AAV injection,Gfap-Cre mice,"Jessica Giehrl‐Schwab, Florian Giesert, et al. Parkinson's disease motor symptoms rescue by CRISPRa‐reprogramming astrocytes into GABAergic neurons. (2022)",https://doi.org/10.15252/emmm.202114797,https://www.embopress.org/cms/10.15252/emmm.202114797/asset/41175184-601d-45a9-b249-dfb3cad7b04e/assets/graphic/emmm202114797-abs-0001-m.png
3.5. Neurodegenerative Diseases,Parkinson's disease,GDNF,activation,SAM,SadCas9,magnetite vehicle meticulously,PD cell model,"Guzmán-Sastoque P, et al. Assessment of CRISPRa-mediated gdnf overexpression in an In vitro Parkinson's disease model. (2024)",https://doi.org/10.3389/fbioe.2024.1420183,https://www.frontiersin.org/files/Articles/1420183/fbioe-12-1420183-HTML-r1/image_m/fbioe-12-1420183-g001.jpg
3.5. Neurodegenerative Diseases,Parkinson's disease,Nrf2,activation,VP64,SadCas9,AAV1-injection,C57BL/6J,"Lau CH, Ho JW, Lo PK, Tin C. Targeted Transgene Activation in the Brain Tissue by Systemic Delivery of Engineered AAV1 Expressing CRISPRa. (2019)",https://doi.org/10.1016/j.omtn.2019.04.015,https://www.cell.com/cms/10.1016/j.omtn.2019.04.015/asset/eea47413-e3c0-4de3-84ab-092ac5012d9c/main.assets/fx1_lrg.jpg
3.5. Neurodegenerative Diseases,Inherited blindness,Opn1mw,activation,VPR,dCas9,rAAV injection,Rho +/−  mice,"Sybille Böhm et al. ,A gene therapy for inherited blindness using dCas9-VPR–mediated transcriptional activation. (2020)",https://doi.org/10.1126/sciadv.aba5614,https://www.science.org/cms/10.1126/sciadv.aba5614/asset/95148248-bf0d-4e55-895e-69074470e020/assets/graphic/aba5614-f1.jpeg
3.5. Neurodegenerative Diseases,Inherited blindness - Retinitis pigmentosa,Nrl,repression,KRAB,intein-split-dCas9,AAV injection,Nrl-GFP mice,"Moreno AM, Fu X, et al. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. (2018)",https://doi.org/10.1016/j.ymthe.2018.04.017,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5896/6035733/32a2b96f9f6c/gr1.jpg
3.6. Psychoneurological Conditions and Addictions,Alcohol use disorders,Arc,activation,p300,dCas9,lentiviral injection,Sprague-Dawley (SD) rats,"John Peyton Bohnsack et al. ,Targeted epigenomic editing ameliorates adult anxiety and excessive drinking after adolescent alcohol exposure. (2022)",https://doi.org/10.1126/sciadv.abn2748,https://www.science.org/cms/10.1126/sciadv.abn2748/asset/55861440-9f8a-4eec-a72f-d01a8d16a605/assets/images/large/sciadv.abn2748-f1.jpg
3.6. Psychoneurological Conditions and Addictions,Chronic pain,SCN9A,repression,KRAB,dCas9,AAV injection,C57BL/6J mice,"Ana M. Moreno et al. ,Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice. (2021)",https://doi.org/10.1126/scitranslmed.aay9056,
3.6. Psychoneurological Conditions and Addictions,Epilepsy,Kcna1,activation,VP64,dCas9,AAV9,Male and female C57BL/6J and Camk2a-Cre mice,"Gaia Colasante, Yichen Qiu, et al. In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. (2020)",https://doi.org/10.1093/brain/awaa045,https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/brain/143/3/10.1093_brain_awaa045/3/m_awaa045f1.jpeg?Expires=1748854290&Signature=UncHptb0NeeIsWQXKG0T5RSYgNkr9wLFRtCC7ZBVQW9B5M5YWUmbQJ4zcCVL7P1ClH34EiW82rsqCjpcfM6pBs3NcBGNQFMrpmbxlbRW4cyHjR-g8sqiVg3zhhalQK6on2fx6aNBcbrccdoKIknU1IPqcrKS9I1yOfXxNEtqvGldtOszyqot7dmNrgnWDlzAzNPS7rvGmG86l2Dx8D9ex970xXt12p~JlAvTi3SRel1IJ-QP1ebS6uUdp0zy3pTgxJGt1VQzTg-vir0N6QucL3KIbu9qX0rORtRH5K2FWi7z85Z5~N8vq2OtHsjagRs~8Hxi2Sf7w2byWonPvluDcA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
3.7. Metabolic Diseases,Atherosclerosis,PCSK9,repression (gene editing),Cas9,Cas9,AAV injection,C57BL/6 mice,"Ding Q, Strong A, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. (2014)",https://doi.org/10.1161/circresaha.115.304351,https://www.ahajournals.org/cms/10.1161/CIRCRESAHA.115.304351/asset/75e61ffe-58aa-4b66-8304-e89c8cbc3a84/assets/graphic/488fig01.jpeg
3.7. Metabolic Diseases,Atherosclerosis,PCSK9,repression (base editing),nCas9,nCas9,mRNA-LNP,"Female C57BL/6J mice, Macaca fascicularis","Musunuru, K., Chadwick, A.C., Mizoguchi, T. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. (2021)",https://doi.org/10.1038/s41586-021-03534-y,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-021-03534-y/MediaObjects/41586_2021_3534_Fig1_HTML.png
3.7. Metabolic Diseases,Atherosclerosis,PCSK9,repression,KRAB,dSaCas9,AAV8 injection (2 vector - cas +sg),male C57Bl/6 mice,"Thakore, P.I., Kwon, J.B., Nelson, C.E. et al. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. (2018)",https://doi.org/10.1038/s41467-018-04048-4,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-04048-4/MediaObjects/41467_2018_4048_Fig1_HTML.jpg?
3.7. Metabolic Diseases,Atherosclerosis,PCSK9,repression,KRAB,dSaCas9,AAV2/8 (1 vector) tail injection,Male C57BL/6 mice,"Backstrom JR, Sheng J, Wang MC, Bernardo-Colón A, Rex TS. Optimization of S. aureus dCas9 and CRISPRi Elements for a Single Adeno-Associated Virus that Targets an Endogenous Gene. (2020)",https://doi.org/10.1016/j.omtm.2020.09.001,https://www.cell.com/cms/10.1016/j.omtm.2020.09.001/asset/ed9417e5-3d4e-4fcb-a662-69875382396a/main.assets/fx1_lrg.jpg
3.7. Metabolic Diseases,Myocardial hypertrophy,Myh6,activation,VPR,dCas9,AAV9 hearts injection (TRISPR ),dCas9VPR  transgenic mice,"Schoger E, Carroll KJ, et al. CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart. (2020)",https://doi.org/10.1161/circresaha.118.314522,https://www.ahajournals.org/cms/10.1161/CIRCRESAHA.118.314522/asset/9a9a7257-e0b0-496e-94ba-ee25efb1be67/assets/graphic/6ga1.jpg
3.7. Metabolic Diseases,Enhancement of Skeletal Muscle Mass,Fst,activation,SAM,dCas9,AAV9 sgRNA tail vein injection,dCas9 transgenic mice,"Liao HK, et al. In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. (2017)",https://doi.org/10.1016/j.cell.2017.10.025,https://www.cell.com/cms/10.1016/j.cell.2017.10.025/asset/4c90254e-38e4-422d-9f8d-31452ee22bba/main.assets/fx1_lrg.jpg
3.7. Metabolic Diseases,Type 1 diabetes,Pdx1,activation,SAM,dCas9 ,AAV9 sgRNA tail vein injection,dCas9 transgenic mice,"Liao HK, et al. In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. (2017)",https://doi.org/10.1016/j.cell.2017.10.025,https://www.cell.com/cms/10.1016/j.cell.2017.10.025/asset/4c90254e-38e4-422d-9f8d-31452ee22bba/main.assets/fx1_lrg.jpg
3.8. Acute Organ Injury and Fibrosis,Fibrosis,"Rasal1, Klotho",activation,dCas9(HF)-TET3CD,dCas9(HF)-TET3CD,lentiviral injection,Rasal1tm1a mice,"Xu, X., Tan, X., Tampe, B. et al. High-fidelity CRISPR/Cas9- based gene-specific hydroxymethylation rescues gene expression and attenuates renal fibrosis. (2016)",https://doi.org/10.1038/s41467-018-05766-5,https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-05766-5/MediaObjects/41467_2018_5766_Fig1_HTML.png?
3.8. Acute Organ Injury and Fibrosis,Fibrosis,Klotho,activation,SAM,dCas9,AAV9 sgRNA tail vein injection,dCas9 transgenic mice,"Liao HK, et al. In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. (2017)",https://doi.org/10.1016/j.cell.2017.10.025,https://www.cell.com/cms/10.1016/j.cell.2017.10.025/asset/4c90254e-38e4-422d-9f8d-31452ee22bba/main.assets/fx1_lrg.jpg
3.9. Normal and Accelerated Aging,Aging,"PDE4C, FHL2, ELOVL2, KLF14, TEAD1",repression,"DNMT3A, CRISPRoff (DNMT3A-DNMT3L-KRAB))",dCas9,transfection,HEK293T,"Sven Liesenfelder, et al. Epigenetic editing at individual age-associated CpGs affects the genome-wide epigenetic aging landscape. (2024)",https://doi.org/10.1101/2024.06.04.597161,https://www.biorxiv.org/content/biorxiv/early/2024/06/05/2024.06.04.597161/F1.medium.gif
3.9. Normal and Accelerated Aging,Hutchinson-Gilford progeria ,Oct4,activation,SAM,dCas9,AuNPs/PEI nanocomplexes,C57BL/6 male mice,"Kim J, Hwang Y, Kim S, et al. Transcriptional activation of endogenous Oct4 via the CRISPR/dCas9 activator ameliorates Hutchinson-Gilford progeria syndrome in mice. (2023)",https://doi.org/10.1111/acel.13825,https://onlinelibrary.wiley.com/cms/asset/6c298579-343d-4aa8-959d-fb5f00ffe85b/acel13825-fig-0001-m.png
3.10. Oncological Diseases,cancer ,"MASPIN, REPRIMO",activation,"VP64, VPR, p300",dCas9,Transfection,"HEK293T, H157, MCF7, SUM159","Garcia-Bloj B, et al. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. (2016)",https://doi.org/10.18632/oncotarget.11142,https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=11142&path%5B%5D=44879&path%5B%5D=210025
3.10. Oncological Diseases,cancer ,"MYOD, IL1RN",activation,p300,dLbCpf1,Transfection,"U2OS, MCF7","Zhang, X., Wang, W., Shan, L. et al. Gene activation in human cells using CRISPR/Cpf1-p300 and CRISPR/Cpf1-SunTag systems. (2018)",https://doi.org/10.1007/s13238-017-0491-6,https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/proteincell/9/4/10.1007_s13238-017-0491-6/2/m_13238_2017_491_fig1_html.gif?Expires=1748266788&Signature=34ti~lM0etBloIJtv8o7BIy7RZwNATj1bVRVBmHdMaRXANIPeTLjguU1UXeqwchaHc72-yuB-bSC0zkn9niUwgTpId8E6iG7fiKJYJIT2jrR06zvyux6PddzwyCm1YXdR~HbBD5NxlYAlJJti-3PmYD0C8WvD-LzojYtWbNGVQ260rSCWHrun~4PU93kEA4Q~i~WE7KMKTUPHvRlMaZDFBKuwMgjIy37XOYaMoFJLoNDAMZC4nxEWUToDmpXmboqOSJ3yWn1Bg0nFGU7urrHBpZFMnZTcJ0Yy9T~JPO42pFza5OhQiejdeOPGs9bsFJhkoKE~f9ZVf3pUnRGaBk6~A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
3.10. Oncological Diseases,cancer ,BRCA1,activation,TET1CD,dCas9,Transfection,"MCF7, HeLa ","Choudhury SR, Cui Y, Lubecka K, Stefanska B, Irudayaraj J. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. (2016)",https://doi.org/10.18632/oncotarget.10234,https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=10234&path%5B%5D=32664&path%5B%5D=157735
3.11. Viral Diseases,Hepatitis B,Hbx,repression,KRAB,ZFP,Ca-P-transfection,Hep3B,"Zhao X, Zhao Z, Guo J, et al. Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line. (2013)",https://doi.org/10.1177/1087057112463066,https://journals.sagepub.com/cms/10.1177/1087057112463066/asset/49d35854-7ace-4074-bc4a-aec07394fdcc/assets/images/large/10.1177_1087057112463066-fig1.jpg
3.11. Viral Diseases,Hepatitis B,EnhI region,repression,KRAB,ZFP,Plasmid injection,C57BL/6-HBV-1.3 mice,"Luo W, Wang J, Xu D, Bai H, Zhang Y, Zhang Y, Li X. Engineered zinc-finger transcription factors inhibit the replication and transcription of HBV in vitro and in vivo. (2018)",https://doi.org/10.3892/ijmm.2018.3396,https://www.spandidos-publications.com/article_images/ijmm/41/4/IJMM-41-04-2169-g00.jpg
3.11. Viral Diseases,Hepatitis B,X protein,repression,DNMT3A,ZFP,injection,M-TgHBV mice,"Xirong, L., Rui, L., Xiaoli, Y. et al. Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter. (2014)",https://doi.org/10.1134/S0006297914020047,http://protein.bio.msu.ru/biokhimiya/contents/v79/full/79020154Fig1.gif
3.11. Viral Diseases,Hepatitis B,"Surface protein, Pol",repression,KRAB,TALE,hydrodynamic injection,NMRI mice,"Bloom, K., Kaldine, H., Cathomen, T. et al. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. (2019)",https://doi.org/10.1186/s12879-019-4436-y,https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12879-019-4436-y/MediaObjects/12879_2019_4436_Fig1_HTML.png
3.11. Viral Diseases,Hepatitis B,APOBEC/AID,activation,p300,SadCas9,RNP-transfection,HepG2,"Kostyushev D, Brezgin S, et al. Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus. (2023)",https://doi.org/10.1016/j.omtn.2023.04.016,https://www.cell.com/cms/10.1016/j.omtn.2023.04.016/asset/10ddd8c9-08d8-4a04-8636-ae1736db7523/main.assets/fx1_lrg.jpg
3.11. Viral Diseases,HIV,U3 5'LTR,latency activation,SunTag-VP64,SpdCas9,transfection,JLat6.3,"Bialek JK, Dunay GA, et al. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. (2016)",https://doi.org/10.1371/journal.pone.0158294,https://journals.plos.org/plosone/article/figure/image?size=large&id=10.1371/journal.pone.0158294.g001
3.11. Viral Diseases,HIV,U3 5'LTR,latency activation,SAM-VP64,SpdCas9,transfection,JLat6.3,"Bialek JK, Dunay GA, et al. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. (2016)",https://doi.org/10.1371/journal.pone.0158294,https://journals.plos.org/plosone/article/figure/image?size=large&id=10.1371/journal.pone.0158294.g002
3.11. Viral Diseases,HIV,U3 5'LTR,latency activation,VP64,dCas9,lipofection,T-cells,"Saayman SM, Lazar DC, et al. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. (2016)",https://doi.org/10.1038/mt.2015.202,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/127b/4786915/fc65ec6a85f9/mt2015202f1.jpg
3.11. Viral Diseases,HIV,U3 5'LTR,latency activation,SunTag-VP64,dCas9,ViaFect transfection,"Jurkat, J-Lat A10.631","Ji H, Jiang Z, Lu P, et al. Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter. (2016)",https://doi.org/10.1038/mt.2016.7,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4799/4786936/b46b4f067ca1/mt20167f1.jpg